Category Archives: Nano medicine

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to crossUS$ 720 Mn by 2026from an estimated valuation of just underUS$ 505 Mn in 2018.

This is indicative of aCAGR of 4.7%during the period2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs.

Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare.

The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer.

This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market.

Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

For Critical Insights On The Triple Negative Breast Cancer Treatment Market, Request For Customization Here @www.persistencemarketresearch.com/requesttion/14305

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy.

Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Company Profiles

For In-Depth Competitive Analysis, AccessNow @www.persistencemarketresearch.com/checkout/14305

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Originally posted here:
Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 - WhaTech Technology and Markets News

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer.

Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints.

These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the global triple-negative breast cancer treatment market revenue to cross $720 Million by 2026 from an estimated valuation of just under $505 Million in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare.

The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

To Remain Ahead Of Your Competitors, Request a Sample Here

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market.

Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy.

Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Company Profiles

For Critical Insights on Market, Request For Methodology of Report @

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer.

Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Related

Read more:
Triple Negative Breast Cancer Treatment Market Combining Therapies - Communal News

1) Best Doctors detected my family's genetic heart disorder - Vicky Churcher

In October, we featured the video premiere of AIG Life's real life case study documentary involving its inspirational intermediary director following her heart attack.

2) Proposed new govt. rules threaten last nail in coffin' for life policy trusts

Back in June, Ruth Gilbert investigated how onerous registration rules would take dealing with trusts from complex to almost impossible.

3) Luke Ashworth: In the space of a year I lost everything'

Ahead of the COVER Mental Health Forum in March, we released a Getting Personal Around Protection' video involving protection consultant Luke Ashworth, who courageously opened up about dealing with tragic loss, the value of reaching out and his battle with anxiety and depression at the event.

4) Crowdfunding the key to unlocking protection conversations?

Aviva's Mark Cracknell explored how advisers can use the topic of crowdfunding as part of protection conversations with clients.

5) reviti: Doing the right thing or smoke and mirrors?

COVER took a deep-dive into whether the new life insurance proposition funded by a global tobacco conglomerate has consumers' best interests at heart.

6) Is DeadHappy breathing new life into insurance?

Are skulls, death wishes and pay-as-you-go protection policies really the future of life insurance? Katie Crook-Davies met DeadHappy founder Phil Zeidler four months after the launch of D2C proposition DeadHappy.

7) Health insurance is evolving but will cheaper products help grow the market?

We crossed paths with the latest innovators of the health insurance market - Equipsme, Medigo and Cignpost - to hear why they are doing things differently.

8) Why is life insurance the cheapest in the world?

CIExpert's Alan Lakey discussed the downward trend for critical illness premiums in the face of the increasing cost of continuous upgrades with Alea Risk's Andrew Wibberley.

9) CIExpert: An in-depth critique of insurer pens

This April Fool's gag from Alan Lakey analysing the look, feel and functionality of industry writing devices given away as freebies was a stroke of genius (forgive the pun!).

10) yulife unlocking the group risk market with gamification?

Katie Crook-Davies spokte to the co-founder and CEO of yulife, Sammy Rubin, to find out about his 'yuniverse'.

11) Simon Thomas: It's so important to have difficult conversations'

Following his powerful closing keynote at the COVER Protection & Health Summit, our Getting Personal Around Protection' series returned with the story of broadcaster Simon Thomas following the tragic loss of his wife.

12) Income Protection: Mental Health under the spotlight

Protection Guru's Adam Higgs weighed up the mental health support available through income protection providers.

13) I was left asking: Who am I?' COVER meets Jonny Wilkinson

England Rugby hero and Vitality ambassador opened up to COVER editor Adam Saville about his mental health journey.

14) Suicide rate hits five-year high - industry reaction

We reached out to three thought-leaders to discuss how our industry can tackle the suicide problem.

15) How WhatsApp is transforming customer service

Vitality's Matthew Dijkstra explored the potential for WhatsApp to revolutionise the customer service experience

16) Blurred lines? The Mental Health First Aid backlash

With companies doing more than ever before to support the mental health of employees, we investigated whether they are getting it right.

17) Five medical revolutions' that will transform healthcare

'Smart' bodies, predictive data mining, stem-cell medicine, nano-scale technology and remote robots all featured in Allianz Care's very sci-fi Future Health, Care and Wellbeing' report.

18) COVER Mental Health Forum: The elephant in the room

In March, over 200 industry professionals attended the inaugural COVER Mental Health Forum in London and we covered the main themes at the event in this tidy review - so you didn't' have to.

19) Emma Thomson: Facebook saved my life'

In our new podcast series, the COVER editor Adam Saville interviewed the Women In Protection Network founder about her recent battle with breast cancer and the true value of protection.

20) Meet Emma: The employee of the future

Jennifer Wallismet ergonomist and human factors consultant Stephen Bowden to discuss Emma, a life-sized model constructed to show the physical impact of workplaces.

More here:
Our top 20 features of 2019 - COVER

Nanomedicine involves smaller particles, yet their capabilities are tremendous, playing a more significant part in the diagnosis and treatment of cancer.

Fremont, CA: Nanomedicine uses particles and technology that is one-billionth of a meter in medicine for diagnosis and treatment of disease. Irrespective of their smaller size, these nanoparticles play a significant role in the medical field. According to cancer.net, nearly 96,480 cases of invasive melanoma of the skin will be diagnosed in 2019 in the US. Even though it is not the most common type of skin cancer, an estimation of 7,230 deaths will occur this year. In recent research, nanomedicine has been employed to help with improving detection, prevention and treatment of a severe form of skin cancer, melanoma.

The disease begins in the melanocytes, which are the cells responsible for the synthesis of a dark pigment called melanin. And when the skin is exposed to the sun for a long time, melanocytes start producing more pigment as a protective response causing the skin to darken more. When these cells grow out of control, it can result in melanoma.

Tel Aviv researchers have developed a nano-vaccine for melanoma. The vaccine was tested in mice, and it turned out to be useful as it prevents the development of melanoma. It also treats both primary tumors and disease that has spread throughout the body. It was observed by administering with immunotherapy that activates the immune system to fight against the foreign cells. Meanwhile, these cells learn to identify the melanoma cells and will start attacking cells of this specific cancer.

The researchers also examined the vaccine in different conditions. They injected the vaccine into healthy mice and then placed the melanoma cells in the mice where the vaccine halted the development of the disease. In another scenario, the vaccine and immunotherapy together were used to treat the mice already infected by melanoma. Here a significant delay in the progression of the disease was observed. Also, peptides which are the short amino acid chains used in the vaccine were present in the samples of melanoma tissue from different sites in the mice's body other than the one where melanoma had been injected initially. This proves that the vaccine is also suitable for patients affected severely for whom melanoma has spread beyond the primary site.

Read more:
What is the Role of Nanomedicine in Treating Melanoma? - Medical Tech Outlook

This month, a paper published by University researchers Richard Terek and Qian Chen highlighted a potential nanotechnology therapy that targets chondrosarcoma, a rare type of bone cancer. Using nanoparticles, the team effectively delivered therapies directly into tumor cells and observed decreases in tumor volume and prolonged survival in mouse models.

Chondrosarcoma currently has no FDA approved treatments. The complex makeup of these cancer cells makes them uniquely difficult to treat. Specifically, one challenge to (drug) delivery in chondrosarcoma is the negatively charged proteoglycan-rich extracellular matrix that needs to be penetrated to reach the tumor cells, according to the study.

Terek, the chief of musculoskeletal oncology at Rhode Island Hospital, an orthopedic oncology surgeon with the Lifespan Cancer Institute and a professor of orthopedic surgery at Warren Alpert, studies chondrosarcoma and collaborated with Chen, a molecular and nano-medicine researcher, director of the NIH-funded Center of Biomedical Research Excellence in Skeletal Health and Repair at Rhode Island Hospital and a professor of orthopedic research and medical science, on this study. The pair aimed to develop a nanopiece delivery platform capable of penetrating the convoluted chondrosarcoma matrix.

We develop nanomaterial (that) we call nanopieces and we found that it can deliver nucleic acid therapeutics to tissues that normally are very difficult to be penetrated, Chen said.

In addition to getting drugs to the tumor tissue, the researchers also studied the biology of how chondrosarcoma spreads. The other thing is we dont totally understand what drives cancer cells to metastasize. That part of the work involves trying to disentangle which types of pathways have gone awry, Terek said.

The underlying principle of the therapy is that miRNA, short 21-nucleotide sequences, are overexpressed in chondrosarcoma tumor cells. These miRNA end up functioning in a way similar to oncogenes, genes which drive cancer formation, by indirectly affecting other genes in the cancer pathway.

Tereks work over the past decade has culminated in the identification of the cancer-causing, or oncogenic, miRNA involved in chondrosarcoma formation. That process involved microarray analysis of primary human tumor tissues. We used a variety of screening techniques to identify which miRNA were overexpressed in tumors, Terek said.

These detrimental effects of the oncogenic miRNA can be prevented by synthesizing a molecule of the opposite sequence of nucleotides. Once delivered into the cell with the nanoparticles it will counteract and annihilate the overexpressed miRNA Terek said.

Once the target miRNA was identified, the small, opposing sequence of RNA needed to be delivered, a process that is normally very difficult because of the charge and structure of the matrix formed by the tumor. What we do in the lab is formulate this nanomaterial specifically for penetrating into the matrix, Chen said.

The laws kind of break down when you get to these nano levels. At the nano level, these particles somehow get through the cell wall and into the cell, even though the cell wall is classically thought of as this impenetrable structure around the cell, Terek said.

The nanomaterial delivery vehicle is composed of a small molecule, weighing about 400 daltons, which assembles into a nanotube structure that contains RNA. The molecule itself is biomimetic. Its half composed of nucleic bases and half of the molecule is amino acids, so its fused together. Because of that it also has a very low level of cell toxicity, Chen said. The nanoparticle is designed to be comparable to a natural biological structure, enabling the particle to be generally accepted by cells, so it can enter and affect them.

In previous studies, Chens lab has shown successful use of nanoparticle therapy in the treatment of multiple other diseases, including rheumatoid arthritis. Recently, they also received a grant from the National Institutes of Health funding research on the treatment of Alzheimers disease using a similar nanopiece delivery system that can traverse the blood brain barrier.

In further developing this drug therapy, Terek said one possibility is to combine multiple miRNA sequences with these nanoparticles to impact more pathways and get maximal inhibition of tumor spread. This involves both counteracting overexpressed miRNA, and restoring beneficial cancer suppressor miRNAs to combine multiple therapeutics with one dose of the nanoparticles.

Another potential approach is to pair the miRNA therapy with other cancer drug therapies. Since some miRNAs prevent the effective use of typical cancer treatment drugs, this approach can be used to reverse drug resistance, allowing for the use of conventional therapies, like chemotherapy.

In order for nanoparticle therapy development to succeed, investors, pharmaceutical companies, biotech companies and other collaborators need to give time and money to projects like this, Chen said. As far as moving it into the clinic, thats always a big hurdle, Terek said. One intermediate step the team might take is to collaborate with veterinarians allowing them to incorporate their treatment method beyond mouse models.

Brown and Lifespan have helped establish a startup called NanoDe so that we can continue the process, Chen said. Moving forward, the team will continue to work on collaborating with other researchers and developers to advance this drug therapy for chondrosarcoma.

Continued here:
Nanoparticle therapy shows promise for treatment of rare cancer - The Brown Daily Herald

According to Stratistics MRC, the Global Nanorobotics Market is accounted for $4.10 Billion in 2017 and is expected to reach $11.88 Billion by 2026 growing at a CAGR of 12.5% during the forecast period. Growing application of nanotechnology and regenerative medicine, rising acceptance and preferment of entrepreneurship and increasing investments by government and universities are the key factors fuelling the market growth. However, high manufacturing cost may hinder the growth of the market.

Nanorobotics is an evolving technology arena that creates robots or machines which have machinery near to the scale of a nanometre (109 meters). It denotes the nanotechnology engineering regulation of planning, designing, and building nanorobots, primarily from molecular components. Nanorobotics is an attractive new field, especially in medicine, which focus on directed drug delivery using nanoscale molecular machines.

Request For Report sample @: https://www.trendsmarketresearch.com/report/sample/11327

By Type, Nanomanipulator is expected to hold considerable market growth during the forecast period. Nanomanipulator is a specialized nanorobot and microscopic viewing system for working with objects on an extremely small scale. Nanomanipulators are mainly used to influence the atoms and molecules and were among the first nanorobotic systems to be commercially accessible. By geography, Europe dominated the highest market share due to rising aging population and rising governmental healthcare expenditure.

Some of the key players in Nanorobotics include Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract and Nanonics Imaging

Types Covered: Nanomanipulator Magnetically Guided Bacteria-Based Bio-Nanorobotics

Applications Covered: Biomedical Nanomedicine Mechanical Other Applications

Request For Discount On This Report at: https://www.trendsmarketresearch.com/report/discount/11327

Regions Covered: North Americao USo Canadao Mexico Europeo Germanyo UKo Italyo Franceo Spaino Rest of Europe Asia Pacifico Japano Chinao Indiao Australiao New Zealando South Koreao Rest of Asia Pacific South Americao Argentinao Brazilo Chileo Rest of South America Middle East & Africao Saudi Arabiao UAEo Qataro South Africao Rest of Middle East & Africa

What our report offers: Market share assessments for the regional and country level segments Market share analysis of the top industry players Strategic recommendations for the new entrants Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping mapping the key common trends Company profiling with detailed strategies, financials, and recent developments Supply chain trends mapping the latest technological advancements

Free Customization Offerings:All the customers of this report will be entitled to receive one of the following free customization options: Company Profilingo Comprehensive profiling of additional market players (up to 3)o SWOT Analysis of key players (up to 3) Regional Segmentationo Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check) Competitive Benchmarkingo Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Read the original here:
NanoRobotics Market Overview on Future Threats by 2026 - Crypto News Byte

Pancreatic cancer is an insidious disease itis often diagnosedat an advanced stage, with about 90% of patients dying within five years of diagnosis.New projections suggest pancreatic cancer will be the second leading cause of cancer mortality by 2025.

This World Pancreatic Cancer Day, we are celebrating some of the many UNSWresearchers who are dedicated to changing those statistics. Cancers with poor outcomes like pancreatic cancer are a key focus area in UNSW Medicine's cancer theme.

Associate Professor Phillips is the Head of the Pancreatic Cancer Translational Research Group and Deputy Director of the Adult Cancer Program at the Lowy Cancer Research Centre at UNSW Medicine.

This year, A/Prof Phillips was a key driver in establishing the Pancreatic Cancer Research Hub, which aims to double the survival of patients with pancreatic cancer by 2030.

She says World Pancreatic Cancer Day is a powerful advocacy event to increase community and government awareness of pancreatic cancer.

It is also a time to reflect on the progress we have made in understanding this terrible disease and focus on the next steps to overcome current clinical challenges to ensure our research efforts bridge the gap and, as in other cancers, improve the outcomes for our patients with pancreatic cancer.

I know that we are on the brink of overturning the unacceptable statistics. Uniting researchers with the community who, unlike in other cancers, dont often get to be a strong voice advocating for themselves and Government will ensure Australian researchers continue to make positive change for pancreatic cancer patients globally.

A/Prof Phillips group has developed a novel cutting-edge way to keep pieces of human pancreatic tumours alive in the laboratory for two weeks after surgical resection.

Our capacity to grow human tumour tissue in the laboratory provides a valuable new clinical tool to test how a patients tumour responds to different chemotherapies and has the potential to immediately inform patient treatment options. Our unique tumour model is superior to other models because it is human in origin and it contains the complex tumour environment present in patients.

In 2016 A/Prof Phillips had a major breakthrough, successfully developing a novel nanomedicine a tiny drug delivery vehicle consisting of a state-of-the-art nanoparticle that can package gene therapy to inhibit any tumour-promoting gene in pancreatic cancer.

With the generous support from the Brian O'Neill Pancreatic Cancer Fundraising Dinner held last night the team will be able to perform essential preclinical studies to test the therapeutic potential of their nano-gene therapy in combination with a clinically approved drug. They also plan on using their expertise to improve the bioavailability of the clinically approved drugs using a nanomedicine approach.

Professor Minoti Apte was the first in the world to isolate and characterise pancreatic stellate cells, a cell type that is now known to play a major role in the progression of both chronic pancreatitis and pancreatic cancer. Coming up with ways to target these cells to prevent them from doing harm is now a major focus of her teams research.

The group has now shown that interrupting the cross-talk between cancer cells and surrounding cells in the microenvironment by targeting a certain signalling pathway reduces tumour growth and eliminates metastasis in early as well as advanced pre-clinical models of pancreatic cancer.

We have also shown that targeting this pathway reduces the risk of recurrence and progression after surgical resection of pancreatic cancer in a mouse model, and are currently working on possible pathways to take our laboratory findings to the clinic, Professor Apte says.

To me, World Pancreatic Cancer Day is a great opportunity to raise awareness in the community about this deadly cancer, but it is also a day to admire the courage and resilience of patients and their carers. These are the people that spur us researchers on to continue working hard to develop new therapeutic approaches to improve outcomes.

Last year, Professor Apte received the Gastroenterological Society of Australia (GESA) Distinguished Researcher Prize 2018. In 2014 she was awarded the Medal of the Order of Australia (OAM), after being named the NSW Woman of the Year in 2015. She was also the 2016 recipient of the Professor Rob Sutherland AO Make a Difference Award at the NSW Premiers Awards for Outstanding Cancer Research an award that recognises highly successful research that is actively changing cancer treatment and improving patient survival.

Dr Angelica Merlot, who is based at the Childrens Cancer Institute, focuses her research on developing new anti-cancer drugs that target drug resistance and suppress cancer spread.

This year, the cancer researcher has won the 2019 NSW Young Woman of the Year award for her achievements and research into treatments for pancreatic and brain cancer. She also won a 2019 Young Tall Poppy Science Award and the 2019 NSW Early Career Researcher of the Year (Biological Sciences) at the NSW Premiers Prizes for Science & Engineering.

Dr Merlot says today is an important day to raise awareness about one of the world's toughest cancers.

This is crucial as it broadens community knowledge, inspires action and supports further research funding for this cancer. It's also a time to remember those whom we have lost and those currently fighting this disease, she says.

Although we've seen a small improvement in the current survival rate, a lot of progress is still required. Further translational research means that there is a greater likelihood that the survival rates can be increased and the journey and treatment of those affected by the cancer can be improved.

Dr Merlot became focused on cancer research as an undergraduate. Her interest in aggressive cancers, such as pancreatic and brain cancer, was motivated by lack of improvement in survival rates over the past decades, largely due to late diagnosis, a lack of screening programs, low awareness of symptoms and a lack of treatment options.

After moving to UNSW Medicine as a Scientia Fellow in 2018, Dr Merlot focused on understanding the mechanisms by which cancer cells grow and adapt to their environment, why drugs become less effective and the development of nanoparticles to improve drug delivery.

Dr Merlots current projects are investigating part of a human cell called the endoplasmic reticulum (ER). The ER is a type of organelle, or subunit within a cell, that has been shown to help cancers grow, spread and develop drug resistance.

Dr Ying Zhu will lead a team of researchers from UNSW to discover much needed early detection methods for pancreatic cancer patients: the UNSW Medicine researcher today received $100,000 grant from the Avner Pancreatic Cancer Foundation. A/Prof Phillips is a co-investigator on this grant.

As current approaches to this research are time and labour intensive, the team will develop an integrated and small device based on nanotechnology for rapid and sensitive exosome analysis. The team will define a set of biomarkers that can differentiate between cancer and non-cancer subjects from cells and plasma carrying early signs of human pancreatic cancer. This novel technology will also be applicable for doctors monitoring the development and customising the treatment of a patients tumour.

Pancreatic cancer is difficult to diagnose in the early stages. Early tumour cant be observed during routine physical exams as the pancreas is deep inside the body. Most patients are diagnosed when the cancer has become very large or has spread to other organs. A method to detect pancreatic cancer early on is urgently needed, Dr Zhu said.

My project team aims to develop a blood test to detect pancreatic cancer in the early stages. The team will target exosomes, which are nanosized fragments released by cancer cells. Exosomes are important for communicating messages and transporting materials between cells. Exosomes have been identified as more accurate and promising biomarkers, or biological clues for pancreatic cancer diagnosis, Dr Zhu continued.

We are pleased to award funding to this innovative project, said Michelle Stewart, CEO of the Avner Pancreatic Cancer Foundation. We are encouraged by the high calibre of the research and believe that investment into projects like these will help us to increase survival for people diagnosed with pancreatic cancer.

Visit link:
World Pancreatic Cancer Day: increasing awareness and inspiring action - UNSW Newsroom

DUBLIN--(BUSINESS WIRE)--The "Global Next-Generation Sequencing (NGS) Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Next-Generation Sequencing (NGS) market is expected to reach $25.09 billion by 2026 growing at a CAGR of 20.6% from 2018 to 2026.

Low cost, high accuracy & speed, and exact outcomes even from low sample input are the fundamental advantages it offers over Sanger's sequencing technique. It is utilized to execute different applications for example, biomarker discovery, oncology studies, personalized medicine, agricultural & animal research, and others. It has streamlined nucleotide analysis and has generally replaced conventional tools of genomics, particularly microarray efficiently. Consequently, these aforementioned factors help in expanding the market share.

Factors such as rise in technological advancements and increase in partnerships & collaborations are driving the market growth. Though, lack of skilled professionals, and ethical & legal limitations are projected to inhibit the growth of the market. Moreover, cloud computing as a potential data management service and lucrative opportunities in emerging markets may provide ample opportunities for the market growth.

By end user, academic institutes & research centers segment acquired significant growth in the market owing to the increasing number of collaborations between the market players and academic & research institutions and on the account of wide usage of these methodologies in research and Ph.D. projects, on-site bioinformatics courses, and workshops across regions, and the development of cost-efficient products and services for researchers is leading to the market growth.

The key vendors mentioned are 10x Genomics, Agilent Technologies Inc, Beckman Coulter (A Subsidiary of Danaher), Becton, Dickinson and Company, BGI, Eurofins Scientific, F. Hoffmann-La Roche AG, Genewiz, Illumina Inc, Macrogen Inc, Oxford Nanopore Technologies Ltd, Pacific Biosciences of California Inc, Perkinelmer Inc, Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in this Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Next-Generation Sequencing (NGS) Market, By Disease

5.1 Introduction

5.2 Rare Disease Diagnostics

5.3 Cardiovascular

5.4 Other Diseases

6 Global Next-Generation Sequencing (NGS) Market, By Service

6.1 Introduction

6.2 Sequencing Services

6.3 Animal & Plant Sequencing

6.4 Gene Regulation Services

6.5 Human Genome Sequencing Services

6.6 Microbial Genome - based Sequencing Services

6.7 Single Cell Sequencing Services

7 Global Next-Generation Sequencing (NGS) Market, By Type of Sequencing

7.1 Introduction

7.2 CHIP Sequencing

7.3 De Novo Sequencing

7.4 Illumina Sequencing

7.5 Methyl Sequencing

7.6 Pre-Sequencing

7.7 RNA Sequencing

7.8 Targeted Sequencing & Resequencing

7.9 Whole Exome Sequencing

7.10 Whole Genome Sequencing

8 Global Next-Generation Sequencing (NGS) Market, By Informatics

8.1 Introduction

8.2 Primary and Secondary Data Analysis Tools

8.3 NGS Informatics Services

8.4 Computing

8.5 Storage

8.6 LIMS (Laboratory Information Management System)

8.7 Biological Interpretation and Reporting Tools

9 Global Next-Generation Sequencing (NGS) Market, By Product

9.1 Introduction

9.2 Reagents & Consumables

9.3 Instruments

9.4 Platforms

9.5 Software

9.6 Services

10 Global Next-Generation Sequencing (NGS) Market, By Technology

10.1 Introduction

10.2 454 Technology

10.3 DNA Nano Ball Sequencing

10.4 Ion Semiconductor Sequencing

10.5 Ion Torrent Sequencing

10.6 Ion Semiconductor Sequencing

10.7 Massively Parallel Signature Sequencing (MPSS)

10.8 Nanopore Sequencing

10.9 Pyrosequencing

10.10 Reversible Terminator Sequencing

10.11 Sequencing by Ligation (SBL)

10.12 Sequencing By Synthesis

10.13 Sequencing by Synthesis (SBS)

10.14 Single Molecule Real Time (SMRT) Sequencing

10.15 Single-Molecule Real-Time Sequencing

10.16 Supported Oligonucleotide Ligation and Detection (SOLiD)

11 Global Next-Generation Sequencing (NGS) Market, By Application

11.1 Introduction

11.2 Agrigenomics & Forensics

11.3 Biomarker Discovery and Cancer

11.4 Cardiovascular

11.5 Clinical Investigation

11.6 Consumer Genomics

11.7 Drug Discovery

11.8 Emerging Application

11.9 Forensics

11.20 Genetic Analysis

11.21 Hereditary Disease Detection

11.22 HLA Typing/Immune System Monitoring

11.23 Human Leukocyte Antigen (HLA) Testing

11.24 Infectious Disease Diagnostics

11.25 Life Science

11.26 Metagenomics, Epidemiology & Drug Development

11.27 Oncology

11.28 Pharmaceuticals

11.29 Precision Medicine

11.30 Reproductive Health

12 Global Next-Generation Sequencing (NGS) Market, By End User

12.1 Introduction

12.2 Academic Institutes & Research Centers

12.3 Agriculture and Animal Research

View original post here:
Global Next-Generation Sequencing (NGS) Market Report 2019 - World Market Projected to Surpass $25 Billion by 2026, Rising at a CAGR of 20.6% -...

Nanorobotics Market to 2027 - Global Analysis and Forecasts by Type (Nanomanipulator, Bacteria-Based, Magnetically Guided, Bio-Nanorobotics); Application (Nanomedicine, Mechanical, Biomedical, Others) and Geography. The report studies essential market players such as Bruker, Ginkgo Biowork, Imina Technologies SA, JEOL USA, Kleindiek Nanotechnik, Klocke Nanotechnik

"Worldwide Nanorobotics Market Analysis 2019-2027" is a specialized and in-depth study of the technology industry focusing on the global market trend. The report aims to provide an overview of the global Nanorobotics market with detailed market segmentation by type, application and geography.

The global market for Nanorobotics is expected to grow strongly in the forecasting period. The report contains important statistics on the market status of the leading market participants and offers important trends and opportunities in the market.

Nanorobotics Market report provides an in-depth insight of Industry covering all important parameters including development trends, challenges, opportunities, key manufacturers and competitive analysis. The research report focuses on the leading competitors of the Nanorobotics Market and provides information such as the company overview, product portfolio, key developments, price, cost, value, volume, revenue, capacity, production, and contact information.

Get Sample Copy of this Report atbit.ly/2KFhG20

The report also includes the profiles of key nanorobotics companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of the last three years, key developments in the past five years.

- Bruker Corporation- Ginkgo Bioworks- Imina Technologies SA- JEOL USA, Inc.- Kleindiek Nanotechnik GmbH- Klocke Nanotechnik GmbH- Nanonics Imaging Ltd.- Oxford Instruments plc- Thermo Fisher Scientific- Toronto Nano Instrumentation

The nanorobotics is the science of creating robots or machines with components in the range of the Nanoscale. Increasing government support in the nanorobotics and high investments are positively influencing the current market landscape.

The major players of the nanorobotics market are adopting various strategies such as product launches, acquisition, and collaborations to stay competitive and grow in the global market.

The nanorobotics market is anticipated to witness high growth in the forecast period with increasing investments in nanorobotics combined with growing advancements in molecular robots. Enhanced focus on regenerative medicine and nanotechnology are likely to further fuel the growth of the nanorobotics market.

However, heavy custom duty in medical may hinder the growth of the nanorobotics market during the forecast period. On the other hand, emerging markets offer lucrative opportunities for the growth of the nanorobotics market, and the players involved in the coming years.

The global nanorobotics market is segmented on the basis of type and application. Based on type, the market is segmented as nanomanipulator, bacteria-based, magnetically guided, and bio-nanorobotics.

On the basis of the application, the market is segmented as nanomedicine, mechanical, biomedical, and others.

Inquire about this Report atbit.ly/2D4BOX2

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global nanorobotics market based on various segments.

It also provides market size and forecast estimates from the year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The nanorobotics market by each region is later sub-segmented by respective countries and segments.

The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting nanorobotics market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period, i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South & Central America after evaluating political, economic, social and technological factors affecting the nanorobotics market in these regions.

The reports cover key developments in the nanorobotics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events.

Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved the way for the expansion of business and customer base of market players.

The market players from nanorobotics market are anticipated to lucrative growth opportunities in the future with the rising demand for nanorobotics in the global market. Below mentioned is the list of few companies engaged in the nanorobotics market.

AccessNow@bit.ly/2OtcaRk

- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Nanorobotics Market- Highlights key business priorities in order to assist companies to realign their business strategies.- The key findings and recommendations highlight crucial progressive industry trends in the global Nanorobotics Market, thereby allowing players across the value chain to develop effective long-term strategies.- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more from the original source:
Nanorobotics Market analysis and outlook for 2019-202 available in the latest report - WhaTech - WhaTech

Florida Poly assistant professor Dr. Ajeet Kaushik has received the 2019 USERN Prize in biological sciences, an international award recognizing his work in the field of nanomaterials for the detection and treatment of diseases.

LAKELAND, Fla., Nov. 18, 2019 /PRNewswire-PRWeb/ -- Dr. Ajeet Kaushik is determined to make detecting and treating diseases easy, accessible, and precise through the use of nanomaterials for biosensing and medicine.

His extensive work and resolute desire to improve the delivery of healthcare has earned Kaushik the prestigious Universal Scientific Education Research Network (USERN) Prize. He was named a laureate in the field of biological sciences during the group's fourth annual congress on Nov. 8 in Budapest, Hungary.

USERN, a non-governmental, non-profit organization and network dedicated to non-military scientific advances, is committed to exploring science beyond international borders.

"I was speechless for a while," said Kaushik, who is an assistant professor of chemistry at Florida Polytechnic University.

Kaushik did not attend the awards ceremony in person but did submit a video to be played at the event. He was among hundreds vying for the prize and one of five people who were recognized in different areas of study.

His submitted project, Nano-Bio-Technology for Personalized Health Care, focuses on using nanomaterials to create biosensors that will detect the markers of a disease at very low levels.

"Biosensing is not a new concept, but now we are making devices that are smarter and more capable," Kaushik said.

He cited the recent zika virus epidemic that affected pregnant women and their fetuses, leading to significant health complications upon birth. "There was a demand to have a system that could detect the virus protein at a very low level, but there was no device. There was no diagnostic system," he said.

Kaushik worked on the development of a smart zika sensor that could detect the disease at these low levels. "The kind of systems I'm focusing on can be customized in a way that we carry like a cell phone and do the tests wherever we need to do them," he said.

In addition to using nanotechnology for the detection of diseases like zika, his research on nanoparticles is advancing efforts to precisely deliver medicine to a specific part of the body without affecting surrounding tissue or other parts of the body.

"The drugs we use now do not go only where they need to go, or sometimes they have side effects. We are treating one disease but creating other symptoms," Kaushik said. "I'm exploring nanotechnology that can carry a drug, selectively go to a place, and release the drug so we avoid using excessive drugs."

This nanomedicine could be used to precisely target brain tumors or other difficult-to-treat conditions. He has published papers in scientific journals about this work and also holds multiple patents.

"My whole approach is using smart material science for better health for everybody, which is accessible to everybody everywhere," Kaushik said.

In addition to his USERN prize, Kaushik was named a USERN junior ambassador for 2020 and will work to advance the organization's mission in the United States.

For the most recent university news, visit Florida Poly News.

About Florida Polytechnic University:

Florida Polytechnic University is accredited by the Southern Association of Colleges and Schools Commission on Colleges and is a member of the State University System of Florida. It is the only state university dedicated exclusively to STEM and offers ABET accredited degrees. Florida Poly is a powerful economic engine within the state of Florida, blending applied research with industry partnerships to give students an academically rigorous education with real-world relevance. Connect with Florida Poly online at http://www.floridapoly.edu.

Continue reading here:
Nanotechnology for disease diagnosis and treatment earns Florida Poly professor international award - Yahoo Finance